Ongoing Clinical Trials in Rare GU Malignancies

Andrea B. Apolo, MD, of National Cancer Institute, shares the trials in progress she presented at the 2024 American Society of Clinical Oncology Annual Meeting, including SMART, LASER, and E-VIRTUE.

SMART is a phase 2 study of sacituzumab govitecan with or without atezolizumab immunotherapy in rare genitourinary tumors, including small cell adenocarcinoma, squamous cell bladder/urinary tract cancer, renal medullary carcinoma, and penile cancer.

LASER is a phase 2 study of lurbinectedin with or without avelumab in small cell carcinoma of the bladder.

E-VIRTUE is a phase 2 multicenter study of enfortumab vedotin with or without pembrolizumab in urinary tract adenocarcinoma, urinary tract squamous cell carcinoma, and testicular germ cell tumors.